Skip to main content
Click here to get access to our Free Course on Momentum Investing Strategy

NSE · METROPOLIS

METROPOLIS

HealthcareHealthcare Services₹11699 cr market cap
₹562.45 ▼ -0.33% today As of 19 Nov 2026
52-week low ₹421.7552-week high ₹602.10

-6.3% from the 52-week high · +33.8% above the low

Metropolis Healthcare Ltd. owns and operates medical laboratories. The company is headquartered in Gurgaon, Haryana and currently employs 4,289 full-time employees. The company went IPO on 2019-04-15. The firm offers a range of clinical laboratory tests and profiles, which are used for prediction, early detection, diagnostic screening, confirmation and monitoring of the disease. The firm also offers analytical and support services to clinical research organizations for their clinical research projects. Its services include pathology testing services, corporate wellness, lab in hospitals and clinical research services. The firm offers a range of tests and profiles that include advanced tests in diagnosis of cancer, neurological disorders, infectious diseases, and an array of genetic abnormalities. The company owns a chain of diagnostic centers across India, South Asia, Africa and the Middle East. The firm has spread its footprint across 20 Indian states and over 210 cities.

The short version. METROPOLIS reported revenue of ₹497 crore for Sep 2026, up 15.9% from a year earlier. Net profit was ₹75 crore (up 41.5% year on year). Return on equity was 12.6% in Mar 2026. Promoter holding was 47.82% in Sep 2026, down 1.58 points over 8 quarters.

1 · The price

How has the stock traded?

METROPOLIS trades 6.3% below its 52-week high and 33.8% above its 52-week low.

Change over period: —

1M+8.7%
3M+1.7%
6M+8.9%
1Y+17.0%

2 · The business

Is it growing?

Sales, year on year+15.9%

Sep 2026 revenue of ₹497 cr.

Profit, year on year+41.5%

Sep 2026 net profit of ₹75 cr.

Net margin15.2%

2.9 pts higher than a year earlier.

3-year growth10.0% profit

Revenue compounded at 12.8% over the same 3 years.

Reported results · ₹ crore

Revenue and profit

Show the numbers

Quarterly

Sep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024
Revenue497450425406429386345323
Net profit7557514153452931
Net margin %15.212.612.010.212.311.78.49.7
EPS (₹)3.632.732.462.02.542.171.411.53

Annual

FY2026FY2025FY2024FY2023FY2022FY2021FY2020FY2019
Revenue16461331120811481228998856761
Net profit190145128143214183127120
Net margin %11.510.910.612.417.418.314.915.8
EPS (₹)9.177.06.246.9810.468.956.295.99

3 · The quality

How well does it turn capital into profit?

Return on equity was 12.6% in Mar 2026; debt to equity is 0.01.

Profitability · 4 years

Returns and margins

Mar 2026Mar 2025Mar 2024Mar 2023
Return on equity %12.610.911.714.5
Return on capital %15.713.315.117.3
EBITDA margin %25.023.624.026.1
Net margin %11.410.810.512.3

Compound growth

Revenue vs profit

3 years5 years
Revenue CAGR12.8%10.6%
Profit CAGR10.0%0.7%
Debt to equity0.01
Interest cover11.6x
Current ratio1.40
P/E ratio52.6

4 · The owners

Who holds it, and are they adding?

Promoter holding47.82%

Down 1.58 pts over 8 quarters.

Foreign institutions11.67%

Down 5.06 pts over 8 quarters.

Domestic institutions35.49%

Up 5.49 pts over 8 quarters.

Mutual fund schemes72

+12 versus the previous month.

Shareholding pattern (%)

Quarter by quarter

Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026Sep 2026Change
Promoter49.448.948.8948.8948.8848.8748.8647.82-1.58
FII16.7315.2912.8312.5211.6910.4311.0311.67-5.06
DII30.030.332.433.134.7335.7935.1235.49+5.49
Public3.875.525.885.494.714.914.995.02+1.15

Mutual fund holdings · Oct 2026

72 schemes hold this stock

60 the month before.

  • TATA BUSINESS CYCLE FUND4.54% of NAV
  • LIC MF HEALTHCARE FUND3.73% of NAV
  • Franklin India Opportunities Fund2.4% of NAV
  • Kotak ESG Exclusionary Strategy Fund2.17% of NAV
  • TATA CHILDRENS FUND2.11% of NAV
  • Franklin India Small Cap Fund2.06% of NAV
  • Kotak Small Cap Fund1.94% of NAV
  • THE WEALTH COMPANY SMALL CAP FUND1.89% of NAV

See what mutual funds are buying

5 · The model view

What does our factor model say?

Factor scores, model flags and screen results for METROPOLIS are part of the Wright portfolio review.

Run your free portfolio review

Watchouts

What to review

Model flags are shown inside the portfolio review, alongside your other holdings.

Model ratingLocked
Factor betaLocked
VolatilityLocked

Quick answers

Common questions about METROPOLIS

What is the METROPOLIS share price?

METROPOLIS (METROPOLIS) last closed at ₹562.45, down 0.33% on the day. Its 52-week range is ₹421.75 to ₹602.10.

What is the market cap of METROPOLIS?

METROPOLIS has a market capitalisation of about ₹11,699 crore. Its price-to-earnings ratio is 52.6.

How are METROPOLIS's latest results?

METROPOLIS reported revenue of ₹497 crore for Sep 2026, up 15.9% from a year earlier. Net profit was ₹75 crore (up 41.5% year on year). Return on equity was 12.6% in Mar 2026. Promoter holding was 47.82% in Sep 2026, down 1.58 points over 8 quarters.

Who owns METROPOLIS?

As of Sep 2026, shareholding was: Promoter 47.82%, FII 11.67%, DII 35.49%, Public 5.02%.

How many mutual funds hold METROPOLIS?

72 mutual fund schemes held METROPOLIS in October 2026. That compares with 60 the month before.

Corporate actions

Recent dividends, bonuses and splits

  • 19 May 2026 · Interim Dividend - Rs. 1
  • 20 Mar 2026 · Bonus issue 3:1
  • 11 Nov 2025 · Interim Dividend - Rs. 4
  • 17 Nov 2023 · Interim Dividend - Rs. 4
  • 23 Feb 2023 · Interim Dividend - Rs. 8
  • 21 Feb 2022 · Interim Dividend - Rs. 8

Financials are as reported by the company (consolidated), in ₹ crore. Source: FinEdge exchange filings feed. Figures can differ from other sites because of one-off items and restatements. Callouts above are arithmetic on reported data, not recommendations.

Research data on this page is provided under Wright Research's SEBI Research Analyst registration. The Terms & Conditions of our Research Analyst services apply.